J. Galland

Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study

Maël Heiblig, Marcela A. Ferrada, Matthew T. Koster et al. · Blood · 2022 · 194 citations · Full text

Comparison between idiopathic and VEXAS-relapsing polychondritis: analysis of a French case series of 95 patients

Mohamed-Yacine Khitri, Alexis F. Guédon, Sophie Georgin‐Lavialle et al. · RMD Open · 2022 · 82 citations · Full text

Clinical and pathological features of cutaneous manifestations in VEXAS syndrome: A multicenter retrospective study of 59 cases

Ève Zakine, Loula Papageorgiou, R. Bourguiba et al. · Journal of the American Academy of Dermatology · 2022 · 64 citations · Full text

Vexas Syndrome, Pathology, Clinical Dermatology +6

Pleuropulmonary Manifestations of Vacuoles, E1 Enzyme, X-Linked, Autoinflammatory, Somatic (VEXAS) Syndrome

Raphaël Borie, Marie‐Pierre Debray, Alexis F. Guédon et al. · CHEST Journal · 2022 · 57 citations · Full text

Allergy, Pathology, Pleural Effusion +4

Vasculitis associated with myelodysplastic syndrome and chronic myelomonocytic leukemia: French multicenter case-control study

A.L. Roupie, Alexis F. Guédon, Benjamin Terrier et al. · Seminars in Arthritis and Rheumatism · 2020 · 41 citations · Full text

Hematological Malignancy, Myelodysplastic Syndrome, Vasculitis +7